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Objectives The study tested whether extreme lipoprotein(a) levels and/or corresponding LPA risk genotypes improve myo-
cardial infarction (MI) and coronary heart disease (CHD) risk prediction beyond conventional risk factors.
Background Elevated lipoprotein(a) levels cause MI and CHD. Levels are primarily determined by variation in the LPA gene.
Methods We followed 8,720 Danish participants in a general population study from 1991 to 1994 through 2011 without
losses to follow-up. During this period, 730 and 1,683 first-time MI and CHD events occurred. Using predefined
cutpoints for extreme lipoprotein(a) levels and/or corresponding LPA risk genotypes (kringle IV type 2 [KIV-2])
repeat polymorphism, rs3798220, and rs10455872 single nucleotide polymorphisms), we calculated net reclas-
sification indices from 10% to 10% to 19.9% to 20% absolute 10-year MI and CHD risk.
Results For individuals with lipoprotein(a) levels 80th percentile (47 mg/dl), 23% (p  0.001) of MI events and 12%
(p  0.001) of CHD events were reclassified correctly, while no events were reclassified incorrectly for either
endpoint. As some incorrect reclassification of individuals with no events occurred, addition of lipoprotein(a) lev-
els 80th percentile overall yielded net reclassification indices of 16% (95% confidence interval: 8% to 24%)
and 3% (1% to 8%) for MI and CHD, respectively. Corresponding net reclassification indices for number of
KIV-2 repeats 21st percentile were 12% (5% to 19%) and 4% (0% to 8%), for rs3798220 carrier status
15% (14% to 44%) and 10% (10% to 30%), and for rs10455872 carrier status 16% (6% to 26%) and
2% (1% to 6%). Considering only individuals at 10% to 19.9% absolute 10-year MI and CHD risk, addition of
extreme lipoprotein(a) levels or corresponding LPA risk genotypes improved risk prediction even further.
Conclusions Extreme lipoprotein(a) levels or corresponding LPA KIV-2/rs10455872 risk genotypes substantially improved MI
and CHD risk prediction. (J Am Coll Cardiol 2013;61:1146–56) © 2013 by the American College of Cardiology
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gElevated lipoprotein(a) levels are considered a causal risk
factor for coronary heart disease (CHD) (1,2). Epidemio-
logic studies including meta-analyses have amply demon-
strated a robust and specific association of elevated lipopro-
tein(a) levels with increased risk of CHD (3,4). Of note,
meta-analyses risk estimates may represent minimal esti-
mates as early negative studies using questionable lipopro-
tein(a) measurements are included. We, and others, have
previously reported that in particular extreme levels associate
with a markedly increased risk (5–7), and recent studies of
LPA gene variants strongly support that the association is
causal (8,9). However, data on extreme lipoprotein(a) levels
and/or corresponding LPA risk genotypes are not included
in current cardiovascular risk prediction tools (2,10,11).
Thus, individuals at high risk of CHD due to extreme
lipoprotein(a) levels may remain unidentified.
Recently, a study combining data from 24 prospective
studies reported only slight improvements in cardiovascular
disease risk prediction when adding lipoprotein(a) levels to
conventional risk factors (12). However, even if lipopro-
tein(a), due to its skewed concentration distribution with a
tail toward extremely high levels, will not improve risk
prediction markedly in the average person with low to
moderate levels, lipoprotein(a) measurements has the po-
tential to substantially improve risk prediction in a person
with extreme levels. This corresponds to the common sense
approach of most doctors to only notice and take action
upon lipoprotein(a) levels in the extreme range. The present
paper follows this common sense approach using recom-
mended prediction tools (13,14). SLipoprotein(a) consists of a cholesterol-laden low-density lipo-
protein (LDL)–like particle bound to a plasminogen-like glyco-
protein, apolipoprotein(a) (15). The dual structure suggests that
lipoprotein(a) may be able to contribute to both atherosclerosis
and thrombosis, and recent human genetic data support a role for
lipoprotein(a) in atherosclerotic stenosis in particular (16). Plasma
lipoprotein(a) levels may vary up to a thousand-fold between
healthy individuals and are primarily determined by varia-
tion in the LPA gene coding for apolipoprotein(a) (15).
ost influential is the so-called kringle IV type 2 (KIV-2)
epeat polymorphism defined by a 5.6 kb large repeat that
ay occur between 2 and 40 times per allele, determining
he size of the expressed apolipoprotein(a) protein, the size
f which correlates inversely with plasma lipoprotein(a)
evels (15). Some studies have indicated that in particular
mall isoforms are harmful to an extent not fully explained by
he concomitantly elevated lipoprotein(a) levels (7,17,18). We
ave previously shown that a lower number of KIV-2
epeats associates with increased risk of myocardial infarc-
ion (MI) (8), and in addition, carriers of 2 LPA rare allele
ingle nucleotide polymorphisms (SNPs) (rs3798220 and
s10455872) tagging the KIV-2 repeat polymorphism, have
lso been reported to be at increased risk of CHD (9).
In the present study, we tested the hypothesis that
ddition of information on extreme lipoprotein(a) levels
nd/or corresponding LPA risk genotypes may improve MI
nd CHD risk prediction based on conventional risk factors.
or this purpose, we used a prospective study of the Danish
eneral population, the CCHS (Copenhagen City Heart
tudy), with baseline information on conventional risk
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KIV-2 repeat genotypes, and LPA
rs3798220 and rs10455872 SNPs.
Methods
Participants. The CCHS was
initiated in 1976 to 1978 with
follow-up examinations in 1981
to 1983, 1991 to 1994, and 2001
to 2003 (19). Participants were
randomly selected within age and
sex strata from the Copenhagen
Civil Registration System to re-
flect the general population of
Copenhagen aged 20 to 80
years. For the present study, we
included CCHS 1991 to 1994
examination participants (16,563
invited, 61% response rate) of Danish descent with no prior
history of CHD, who had liproprotein(a) measurements
performed shortly after sampling, and who had a blood
sample available for DNA analyses, as well as complete
information on conventional risk factors (N  8,720) (19).
Approximately half of the included participants also had a
lipoprotein(a) measurement performed in 2001 to 2003,
allowing correction for regression dilution bias (20).
Examinations included a self-administered questionnaire
and a physical examination. Smokers were active smokers,
and diabetes mellitus was defined as self-reported disease,
use of insulin or oral hypoglycemic drugs, and/or a nonfast-
ing plasma glucose of 11 mmol/l. We followed all
individuals from baseline in 1991 to 1994 and censored at
the occurrence of CHD (including MI), death, or May
2011, whichever came first. Follow-up was 100% complete,
that is, we did not lose track of a single individual during
follow-up.
Information on diagnoses of MI and CHD (International
Classification of Diseases-8th edition, codes 410 and codes
410-414, respectively, and 10th edition, codes I21-I22 and
I20-I25, respectively) was collected and verified by review-
ing hospital admissions and diagnoses entered in the na-
tional Danish Patient Registry, causes of death entered in
the national Danish Causes of Death Registry, and medical
records from hospitals and general practitioners.
The study was approved by Herlev Hospital and a Danish
ethical committee (No. KF-100.2039/91) and was con-
ducted according to the Declaration of Helsinki. All par-
ticipants gave written informed consent.
Laboratory analyses. Lipoprotein(a) total mass was mea-
ured using an in-house assay, as described previously(6),
nd as detailed in the Online Appendix and Online Figure
. Enzymatic assays were used on fresh samples to measure
lasma levels of total cholesterol and high-density lipopro-
ein (HDL) cholesterol. The LPA KIV-2 repeat polymor-
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
HDL  high-density
lipoprotein
IDI  integrated
discrimination improvement
KIV-2  kringle IV type 2
LDL  low-density
lipoprotein
MI  myocardial infarction
NRI  net reclassification
index
SNP  single nucleotide
polymorphismphism was genotyped by real-time polymerase chain reac- ption analysis yielding an estimate of the total number of
KIV-2 repeats on both alleles, as described previously(8).
Genotyping for LPA rs3798220 and rs10455872 SNPs
was performed by TaqMan analysis. Genotype distributions
did not differ from those predicted by the Hardy-Weinberg
equilibrium.
Statistical analyses. A priori we focused on individuals with
extreme lipoprotein(a) levels and/or corresponding LPA risk ge-
otypes, as done previously (6,8) and corresponding to the
ommon sense approach of most doctors. Thus, we conducted
nalyses only including individuals with lipoprotein(a) levels
24th,68th,80th,90th, or95th percentile while ignor-
ng persons with the corresponding lower levels, and similarly for
PA risk genotypes. In other words, when examining these
ifferent cutpoints for lipoprotein(a) levels and LPA genotypes,
articipants not included were dropped prior to assessment of
easures of reclassification and discrimination, while underlying
ox regression models were fitted to data from all participants.
or comparison, we also performed analyses including the entire
ange of lipoprotein(a) levels and LPA risk genotypes.
We used Stata version 12.1 (StataCorp LP, College
tation, Texas). Two-sided p  0.05 was considered
ignificant. One-way analysis of variance was used to
stimate the contribution of LPA KIV-2, rs3798220, and
s10455872 genotypes to the variation in plasma lipopro-
ein(a) levels; lipoprotein(a) levels were, for this analysis
olely, square root–transformed due to skewness of the
istribution.
Cox proportional hazards regression was used to estimate
ultivariable adjusted hazard ratios of first-ever MI or
HD events with 95% confidence intervals (CI). We
nalyzed age at event using left-truncation (delayed entry),
nd age as time scale. Analyses were multivariable adjusted
or age, sex, total cholesterol, HDL cholesterol, systolic
lood pressure, smoking, and diabetes mellitus. For this
djustment, total cholesterol values were adjusted for the
ipoprotein(a) contribution, as done previously (6,8), and
ccording to compositional data in which cholesterol ac-
ounts for 30% of total lipoprotein(a) mass (21,22). Based
n the second lipoprotein(a) measurement in 2001 to 2003,
azard ratios for increased lipoprotein(a) levels were cor-
ected for regression dilution bias (20). We used z tests (23)
o test whether hazard ratios for MI differed from hazard
atios for CHD or non-MI CHD.
For estimating measures of reclassification and discrimi-
ation, we first constructed a Cox regression model analyz-
ng time to event (stratified by sex) including only conven-
ional risk factors (age, total cholesterol, HDL cholesterol,
ystolic blood pressure, smoking, and diabetes mellitus).
mportantly, for estimating risk prediction measures, cho-
esterol values were not corrected for the lipoprotein(a)
ontribution. We here derived the baseline survival at 10
ears, S0(10), for each sex and the beta coefficients, 1, 2,
. . . p, for the included covariates, x1, x2,. . .xp (Online
ables 1 and 2 list all beta coefficients included in risk
rediction models). The probability of surviving beyond 10
wp
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as calculated as (12)
Psurv(10)  S0(10)
 exp1x2  2x2  . . .  PxP)
and the probability of an event within 10 years after baseline
was 1 minus the survival probability
Pevent(10)  1Psurv(10)
Deaths from causes other than CHD were considered cen-
sored events, thus, the previous probability refers to risk of an
MI/CHD event in the absence of death from other causes.
Second, we constructed a similar Cox proportional haz-
ards regression model but now including conventional risk
factors plus a new risk factor (lipoprotein(a) level on a
continuous scale, LPA KIV-2 genotype on a continuous
scale, LPA rs3798220 genotype, and/or LPA rs10455872
genotype). Importantly, to avoid favoring lipoprotein(a) in risk
prediction, hazard ratios for increased lipoprotein(a) levels were
not corrected for regression dilution bias in these analyses. We
calculated the new probability of surviving beyond 10 years,
Psurv_new(10), without event, as described previously.
The Cox regression models were fitted to data from all
articipants and then predictive ability was assessed using
easures of reclassification and discrimination, as described
elow. We did not employ cross-validation approaches (i.e.,
erform model derivation and validation in separate subsets
f participants) as the dataset used was of substantial size
inimizing the risk of overfitting. According to Phillips et
l. (24), the beta coefficients are attenuated to k in a
alidation sample where k  1 – (q – 2)/2, q is the number
of parameters in the model, and 2 is the likelihood ratio
chi-square statistic for the model. In our modeling k values
exceeded 0.99 in all main analyses indicating overall negli-
gible bias in regression coefficients from overfitting.
We assessed reclassification in participants with extreme
concentration/genotype levels and with known event status
Baseline Characteristics of ParticipantsTable 1 Baseline Characteristics of Participants
All <24th >24
No. of individuals 8,720 2,055 6,66
Women, % 57 53 5
Age, yrs 59 (46–69) 57 (44–68) 60 (47–
Total cholesterol, mmol/l 6.1 (5.2–6.9) 5.8 (5.0–6.7) 6.1 (5.3
HDL cholesterol, mmol/l 1.5 (1.2–1.9) 1.5 (1.2–1.9) 1.5 (1.2
Systolic BP, mm Hg 136 (122–152) 135 (121–151) 136 (122
Smoking, % 49 51 4
Diabetes, % 4 5
Lipoprotein (a), mg/dl 17 (5–39) 2 (0–3) 25 (13–
LPA KIV-2, no. of repeats 36 (30–41) 38 (33–43) 35 (29–
LPA rs3798220, % carriers 2 1
LPA rs10455872, % carriers 13 1 1Values are n or median (interquartile range).
BP  blood pressure; HDL  high density lipoprotein; KIV-2  kringle IV type 2.at 10 years (i.e., excluding participants censored for other
reasons before 10 years), under the assumption that models
derived from data on all participants, as described previ-
ously, were still applicable. Using the estimated 10-year risk
predictions Psurv(10) and Psurv_new(10), participants were
lassified into 3 a priori defined standard 10-year risk
ategories of 10%, 10% to 19.9%, and 20%. Cross
abulation of the risk categories was stratified by event (MI
r CHD) status at 10 years, and reclassification of partici-
ants between risk categories using Psurv(10) versus using
Psurv_new(10) was examined. Reclassification was deemed
appropriate for participants with events moving up in risk
category and for participants without events moving down
in risk category on addition of the new risk factor. Reclas-
sification was summarized using the net reclassification
index (NRI) and the integrated discrimination improve-
ment (or index) (IDI) (14).
Furthermore, we assessed discrimination over the entire
concentration/genotype levels by computing the C index
(i.e., Harrrell’s C statistic) and difference in C indices
between models with and without new risk factors (25–27).
The C index is the probability that, for a randomly selected
pair of participants, the individual with the shorter survival
time has the higher value of the predictor (1x1  2x2 
. .  pxp). In our case, the predictor included conven-
tional risk factors or conventional risk factors plus new risk
factors, as described previously.
Results
Baseline characteristics of the 8,720 participants are shown
in Table 1. We observed 730 and 1,683 first-time MI and
CHD events during 17 years, and of these, 453 and 1,012
occurred during the first 10 years of follow-up.
Risk of MI and CHD. For lipoprotein(a) levels 80th
(47 mg/dl) or 95th (115 mg/dl) percentile, multivari-
able adjusted hazard ratios were 2.0 (95% CI: 1.5 to 2.7) and
2.5 (1.7 to 3.9) for MI, and 1.5 (1.3 to 1.8) and 1.7 (1.3 to
Lipoprotein(a) Percentiles
>68th >80th >90th >95th
2,851 1,831 959 436
59 60 62 64
60 (49–70) 60 (49–70) 61 (50–70) 62 (53–71)
6.3 (5.4–7.2) 6.4 (5.5–7.3) 6.6 (5.7–7.4) 6.8 (6.0–7.7)
1.5 (1.2–1.9) 1.5 (1.2–1.9) 1.5 (1.2–1.9) 1.6 (1.3–1.9)
137 (123–153) 138 (124–154) 140 (125–155) 140 (126–156)
49 49 49 49
4 4 4 3
59 (40–94) 79 (61–113) 112 (93–137) 139 (125–161)
31 (26–36) 29 (25–34) 28 (24–32) 27 (22–31)
5 8 14 24
39 52 54 47th
5
8
70)
–7.0)
–1.9)
–152)
9
4
52)
40)
3
7
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24th percentile (Fig. 1).
The LPA KIV-2 repeat genotype explained 21% of the
total variation in plasma lipoprotein(a) levels and corre-
lated inversely with levels; median lipoprotein(a) levels
were 10 mg/dl (interquartile range: 3 to 21 mg/dl), 21
mg/dl (7 to 49 mg/dl), 38 mg/dl (11 to 77 mg/dl), 49
mg/dl (17 to 91 mg/dl), 59 mg/dl (28 to 104 mg/dl), and
70 mg/dl (40 to 123 mg/dl) for number of KIV-2 repeats
77th, 77th, 33rd, 21st, 11th, and 6th percen-
Figure 1 Risk of Myocardial Infarction and Coronary Heart Dise
and Corresponding LPA KIV-2, rs3798220, and rs104
Based on 8,720 Danish general population participants, the Copenhagen City Hea
Analyses are multivariable adjusted for age, sex, total cholesterol (corrected for th
sure, smoking, and diabetes mellitus, and also adjusted for regression dilution bia
ard ratios for myocardial infarction and coronary heart disease for each subgroup
kringle IV type 2.tiles, respectively. For KIV-2 repeats 21st or 6th
percentiles, multivariable adjusted hazard ratios were 1.5
(95% CI: 1.2 to 1.8) and 1.9 (95% CI: 1.4 to 2.7) for MI,
and 1.2 (95% CI: 1.0 to 1.3) and 1.5 (95% CI: 1.2 to 1.8)
for CHD, as compared to participants with number of
repeats 77th percentile (Fig. 1).
The LPA rs3798220 genotype (2% carriers) explained
5% of the total variation in plasma lipoprotein(a) levels.
Median lipoprotein(a) levels were 17 mg/dl (interquartile
range: 5 to 38 mg/dl) and 116 mg/dl (21 to 158 mg/dl)
s a Function of Elevated Lipoprotein(a) Levels
2 Risk Genotypes
dy followed from 1991 to 1994 through May 2011 without losses to follow-up.
rotein(a) contribution), high-density lipoprotein cholesterol, systolic blood pres-
alues from z tests show whether there are significant differences between haz-
by lipoprotein(a) levels or LPA genotype. CI  confidence interval; KIV-2 ase a
5587
rt Stu
e lipop
s. p V
defined
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multivariable adjusted hazard ratios of 1.3 (95% CI: 0.8 to
2.1) for MI, and 1.4 (1.1 to 1.9) for CHD, as compared to
noncarriers (Fig. 1).
The LPA rs10455872 genotype (13% carriers) explained
27% of the total variation in plasma lipoprotein(a) levels.
Median lipoprotein(a) levels were 13 mg/dl (interquartile
range: 4 to 28 mg/dl), 69 mg/dl (52 to 98 mg/dl), and 122
mg/dl (103 to 157 mg/dl) for noncarriers, heterozygotes,
and homozygotes, respectively. Heterozygotes and homozy-
gotes had multifactorially adjusted hazard ratios of 1.3 (95%
CI: 1.1 to 1.6) and 1.2 (95% CI: 0.5 to 3.3) for MI, and 1.1
(95% CI: 0.9 to 1.3) and 1.1 (95% CI: 0.5 to 2.1) for CHD,
Figure 2 Reclassification as a Function of Elevated Lipoprotein
Based on 8,720 Danish general population participants, the Copenhagen City Hea
CI  confidence interval; NRI  net reclassification index.as compared to noncarriers (Fig. 1).Comparing MI and CHD hazard ratios yielded z test
p values of 0.12 to 0.41 for elevated lipoprotein(a) levels,
and of 0.09 to 0.82 for LPA risk genotypes (Fig. 1). When
comparing MI and non-MI CHD (i.e., excluding individ-
uals who developed MI during follow-up) hazard ratios,
z test p values ranged from 0.03 to 0.24 for elevated
lipoprotein(a) levels and from 0.01 to 0.68 for LPA risk
genotypes (Online Fig. 2).
Reclassification and discrimination upon addition of
lipoprotein(a) levels. Addition of extreme lipoprotein(a)
levels to models based on conventional risk factors improved
event classification (Fig. 2), for example, for lipoprotein(a)
levels 80th (47 mg/dl) or 95th (115 mg/dl) percen-
evels
dy followed from 1991 to 1994 through May 2011 without losses to follow-up.(a) L
rt Stutiles, 23% (p  0.001) and 39% (p  0.001) of MI events,
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were reclassified correctly, while no events were reclassified
incorrectly for either endpoint. For these cutpoints, incor-
rect reclassification of no events were 7% (p  0.001) and
16% (p  0.001) for MI, yielding NRIs of 16% (8% to
24%) and23% (6% to 39%), and 8% (p 0.001) and 19%
(p  0.001) for CHD, yielding NRIs of 3% (1% to 8%)
and 6% (5% to 17%) (Fig. 2).
Discrimination was also improved, using these cutpoints,
as indicated by IDIs of 0.017 (0.012 to 0.022) and 0.024
(0.011 to 0.037) for MI, and of 0.015 (0.012 to 0.018) and
0.022 (0.015 to 0.029) for CHD.
In comparison, addition of lipoprotein(a) over the entire
concentration range to models based on conventional risk
factors did not significantly improve reclassification yielding
NRIs of 2% (1% to 5%) and 1% (1% to 2%) for MI
and CHD, respectively. Discrimination was improved
slightly, however, as indicated by corresponding IDIs of
0.002 (0.000 to 0.004) and 0.002 (0.001 to 0.003), while C
index changes of 0.0024 (0.001 to 0.0049) and 0.0010
(0.001 to 0.0021) remained insignificant.
When considering only individuals at 10% to 19.9%
absolute 10-year risk (intermediate risk) of MI or CHD
based on conventional risk factors, addition of extreme
lipoprotein(a) levels to models resulted in an overall more
pronounced reclassification of events and non-events
(Online Fig. 3). Also, addition of lipoprotein(a) over the
entire concentration range, among those at intermediate
risk, improved reclassification for MI and CHD yielding
NRIs of 7 (0% to 13%) and 6% (3% to 9%).
Reclassification and discrimination upon addition of
LPA risk genotypes. Addition of information on carrier
status for LPA risk genotypes to models based on conven-
ional risk factors improved event classification (Table 2,
ig. 3). Results for MI and CHD event and nonevent
eclassification for KIV-2 risk genotypes were similar, although
lightly attenuated (Fig. 3), compared to those obtained for
xtreme lipoprotein(a) levels (Fig. 2). NRIs for KIV-2 repeats
21st and 6th percentile were 12% (5% to 19%) and
12% (2% to 26%) for MI and 4% (0% to 8%) and 3%
5% to 11%) for CHD (Fig. 3). Corresponding IDIs for
hese cutpoints were 0.017 (0.013 to 0.022) (Table 2) and
.022 (0.013 to 0.032) for MI, and 0.009 (0.008 to 0.011)
Table 2) and 0.013 (0.009 to 0.016) for CHD.
NRIs for LPA SNPs rs3798220 and rs10455872 risk
enotypes (i.e., minor allele carriers) were 15% (14% to
4%) and 16% (6% to 26%) for MI, and 10% (10% to
0%) and 2% (1% to 6%) for CHD (Table 2). Corre-
ponding IDIs were 0.011 (0.005 to 0.018) and 0.011
0.008 to 0.015) for MI, and 0.029 (0.018 to 0.040) and
.002 (0.002 to 0.003) for CHD (Table 2).
In comparison, addition of LPA genotypes overall (i.e.,
ncluding also carriers of LPA nonrisk genotypes) to models
ased on conventional risk factors did not or only very
lightly improve reclassification yielding NRIs for MI and
HD of 1% (3% to 4%) and 0% (1% to 2%) for hIV-2 repeats, and of 0% (0% to 1%) and 0% (0% to 1%) for
NP rs3798220, and of 1% (1% to 3%) and 1% (0%
o 1%) for SNP rs10455872. Corresponding IDIs were
.003 (0.001 to 0.005) and 0.001 (0.000 to 0.002) for KIV-2
epeats, and equaled zero for either endpoint for both LPA
NPs. Corresponding C-index changes were 0.0032
0.0005 to 0.0059) and 0.0007 (0.0002 to 0.0016) for
IV-2 repeats, and remained insignificant for either end-
oint for both SNPs.
When considering only individuals at 10% to 19.9%
bsolute 10-year risk (intermediate risk) of MI or CHD
ased on conventional risk factors, addition of LPA KIV-2
isk genotypes to models resulted in an overall more
ronounced reclassification of events and non-events
Online Fig. 4). Also, addition of LPA KIV-2 genotypes
verall, among those at intermediate risk, improved reclas-
ification for MI and CHD yielding NRIs of6% (2% to
3%) and 7% (4% to 10%).
eclassification and discrimination upon addition of
xtreme lipoprotein(a) levels and LPA risk genotypes
ombined. Combining extreme lipoprotein(a) levels
80th percentile) with LPA KIV-2 and/or SNP risk
enotypes did somewhat improve values for NRI and IDI
or MI beyond what could be achieved with addition of only
xtreme lipoprotein(a) levels or corresponding risk geno-
ypes separately (Table 2). This was attenuated for CHD.
iscussion
e here demonstrate that extreme lipoprotein(a) levels or
orresponding LPA risk genotypes can substantially improve
I and CHD risk prediction in a general population
etting, a novel finding (2). Importantly, our common sense
pproach of focusing exclusively on extreme lipoprotein(a)
evels and corresponding LPA risk genotypes completely
liminated incorrect reclassification of MI/CHD events,
hat is, no individuals who developed an event during 10
ears of follow-up were incorrectly reclassified down to a
ower risk category. Simply put, an approach of widespread
ipoprotein(a) measurements (or LPA genotyping) to iden-
ify individuals with extreme levels may substantially im-
rove MI/CHD risk prediction for this group representing
p to one fifth of the general adult population. Alterna-
ively, and to limit cost, lipoprotein(a) screening may be
imited to individuals at intermediate risk of CHD (based
n conventional risk factors), where reclassification due to
xtreme lipoprotein(a) levels was even more pronounced. Of
ote, lipoprotein(a) measurements are also likely to be
ost-effective since a single measure of lipoprotein(a) is
enerally sufficient given the stability of levels over time.
xtreme lipoprotein(a) levels, LPA risk genotypes, and
isk prediction. A unique feature of lipoprotein(a), as
ompared to other lipid cardiovascular risk factors such as
otal, LDL, and HDL cholesterol, is the highly skewed
oncentration distribution with a long tail toward extremely
igh values (15). Lipoprotein(a) levels may thus vary up to
Values of NRI and IDI for Myocardial Infarction and Coronary Heart Disease for Extreme Lipoprotein(a) Levels,for Ri k LPA Ge otypes, and for Combinations of Extreme Levels and Risk Genotyp sTable 2 Values of NRI and IDI for Myocardi l Infarction and Coronary Heart Diseas for Extreme Lipoprotein(a) Levels,for Risk LPA Genotypes, and for Combinations of Extreme Levels and Risk Genotypes
Lp(a) >80th %
LPA KIV-2 Repeats
<21st %
LPA rs3798220 Carrier
( Heterozygote)
LPA rs10455872 Carrier
( Heterozygote or
Homozygote)
Lp(a) >80th % and
LPA KIV-2 Repeats
<21st %
Lp(a) >80th % and
LPA rs3798220 or
rs10455872 Carrier Combination of All
Myocardial infarction
NRI, % 16 (8 to 24) 12 (5 to 19) 15 (14 to 44) 16 (6 to 26) 21 (9 to 32) 19 (8 to 29) 19 (5 to 34)
Events 121 110 9 69 65 65 41
app. 28 20 2 14 21 16 12
inapp. 0 0 0 0 0 0 0
p value 0.001 0.001 0.16 0.001 0.001 0.001 0.001
No event 1,369 1,406 160 925 710 846 494
app. 0 0 0 0 0 0 0
inapp. 96 86 11 40 83 50 50
p value 0.001 0.001 0.001 0.001 0.001 0.001 0.001
IDI 0.017 (0.012 to 0.022) 0.017 (0.013 to 0.022) 0.011 (0.005 to 0.018) 0.011 (0.008 to 0.015) 0.025 (0.016 to 0.033) 0.018 (0.010 to 0.025) 0.019 (0.009 to 0.029)
Coronary heart disease
NRI, % 3 (1 to 8) 4 (0 to 8) 10 (10 to 30) 2 (1 to 6) 4 (3 to 11) 3 (2 to 9) 4 (3 to 12)
Events 250 227 22 142 130 134 83
app. 29 22 6 6 19 13 11
inapp. 0 0 0 0 0 1 0
p value 0.001 0.001 0.01 0.01 0.001 0.001 0.001
No event 1,287 1,329 152 872 667 795 463
app. 0 0 0 0 0 2 0
inapp. 106 71 26 16 71 47 41
p value 0.001 0.001 0.001 0.001 0.001 0.001 0.001
IDI 0.015 (0.012 to 0.018) 0.009 (0.008 to 0.011) 0.029 (0.018 to 0.040) 0.002 (0.002 to 0.003) 0.016 (0.012 to 0.021) 0.011 (0.005 to 0.017) 0.010 (0.003 to 0.018)
Values are n, unless otherwise stated. 95% confidence intervals for NRI and IDI values are shown in parentheses. Calculations on NRI and IDI include only participants with known cardiovascular disease status at 10-year follow-up.
app.  appropriate reclassification; IDI  integrated discrimination index; inapp.  inappropriate reclassification; Lp(a)  lipoprotein(a); NRI  net reclassification index;
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Lipoprotein(a) and Cardiovascular Risk Prediction March 19, 2013:1146–56a 1,000-fold among healthy individuals (0.2 to 200
mg/dl) (15) and approximately 20% of individuals are found
in the tail part of the distribution (2). Previous studies have
demonstrated that although risk of CHD may increase
already at moderately elevated lipoprotein(a) levels, risk is
most pronounced for extreme levels (5,6). Thus, considering
the entire range of lipoprotein(a) levels in estimating mea-
sures of reclassification and discrimination may not ade-
quately capture the potential of extreme levels to substan-
tially improve MI and CHD risk prediction for individuals
in the tail part of the lipoprotein(a) distribution. This notion
is supported by our results, demonstrating slight or no
significant increases in NRIs or improvement of discrimi-
Figure 3 Reclassification as a Function of LPA KIV-2 Repeat G
Based on 8,720 Danish general population participants, the Copenhagen City Hea
Abbreviations as in Figures 1 and 2.nation when considering the entire range of lipoprotein(a)levels/genotypes, in accordance with recent results from The
Emerging Risk Factors Collaboration (12).
Some previous studies have indicated that small apolipo-
protein(a) isoforms may be particularly harmful to an extent
not fully explained by the associated higher lipoprotein(a)
levels (7,17,18). Thus, LPA genotypes influencing not only
levels of lipoprotein(a), but also reflecting size wise and
structural apolipoprotein(a) differences, may potentially add
incremental information to lipoprotein(a) levels in CHD
risk prediction. We observed similar improvements in mea-
sures of reclassification and discrimination for extreme
lipoprotein(a) levels and corresponding LPA KIV-2 and
rs10455872 risk genotypes, while the LPA rs3798220 risk
pe
dy followed from 1991 to 1994 through May 2011 without losses to follow-up.enoty
rt Stugenotype did not significantly improve reclassification and
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March 19, 2013:1146–56 Lipoprotein(a) and Cardiovascular Risk Predictiononly slightly discrimination. Of note, the rarity of
rs3798220 carrier status (2%) severely limits statistical
power to detect any predictive effect. When adding both
extreme lipoprotein(a) levels and corresponding LPA KIV-2
and/or SNP risk genotypes to conventional risk factors,
reclassification and discrimination improved somewhat for
MI beyond what could be seen for adding solely extreme
lipoprotein(a) levels or corresponding LPA KIV-2 or
s10455872 risk genotypes. This additive genotype effect
ay reflect that genetic variants are better markers of
ong-term lipoprotein(a) levels than single plasma measure-
ents, and/or that small apolipoprotein(a) isoforms (en-
oded by LPA risk genotypes) are particularly harmful and
onfer atherogenicity beyond effects on hepatic lipopro-
ein(a) secretion and plasma levels. Although this topic
eeds further studies and scrutiny, our data do to some
xtent support adding both extreme lipoprotein(a) levels and
orresponding LPA risk genotypes to conventional risk
actors in risk prediction.
Overall, extreme lipoprotein(a) levels and corresponding
PA risk genotypes appeared better predictors of MI than of
HD, and NRI values appeared more pronounced for MI
han for CHD. This may reflect a prothrombotic effect of
ipoprotein(a), in addition to a proatherosclerotic and/or
rostenotic effect, promoting MI in particular. Of note, we
ave previously reported an increased risk of deep venous
hrombosis for (exclusively) extreme lipoprotein(a) levels
95th percentile and corresponding LPA KIV-2 risk geno-
ypes (16). Alternatively, the difference may reflect some
egree of misclassification of non-MI CHD, a less hard
ndpoint than MI.
tudy limitations. The present study is not the first study
o report on lipoprotein(a) and CHD risk prediction (12).
owever, no previous studies have explored the use of
xtreme lipoprotein(a) levels and corresponding LPA risk
genotypes in risk prediction. A limitation of our study is
that we only studied white individuals, and thus, results may
not necessarily apply to other ethnicities, particularly as
lipoprotein(a) levels and distributions differ between differ-
ent ethnic groups (15). Another limitation of our study is
that our KIV-2 genotype reflects the sum of repeats on both
alleles, and therefore assumes an additive effect of both
alleles on lipoprotein(a) levels. Thus, it is possible that a
more refined measure of the KIV-2 genotype may be able to
add further incremental value to lipoprotein(a) levels in MI
and CHD risk prediction. Finally, we compared MI and
CHD hazard ratios using z tests, not entirely appropriate as
the 2 endpoints are not independent, however, we also
compared MI to non-MI CHD hazard ratios where no
diseased participants overlapped.
Conclusions
We provide novel evidence that adding information on
extreme lipoprotein(a) levels (or corresponding LPA KIV2
or rs10455872 risk genotypes) to conventional risk factorsmay substantially improve MI and CHD risk prediction.
Additional identified individuals at increased risk may
hopefully benefit from aggressive prophylactic measures,
including statins for LDL-cholesterol lowering and possibly
niacin treatment for lipoprotein(a) lowering, as recently
recommended (2).
Acknowledgments
The authors thank laboratory technicians Anja Jochumsen
and Preben Galasz for their excellent technical assistance.
Reprint requests and correspondence: Dr. Børge G. Nordest-
gaard, Department of Clinical Biochemistry, Herlev Hospital,
Copenhagen University Hospital, Herlev Ringvej 75, DK-2730
Herlev, Denmark. E-mail: Boerge.Nordestgaard@regionh.dk.
REFERENCES
1. Kamstrup PR. Lipoprotein(a) and ischemic heart disease—a causal
association? A review. Atherosclerosis 2010;211:15–23.
2. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a
cardiovascular risk factor: current status. Eur Heart J 2010;31:
2844 –53.
3. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart
disease. Meta-analysis of prospective studies. Circulation 2000;102:
1082–5.
4. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and
the risk of coronary heart disease, stroke, and nonvascular mortality.
JAMA 2009;302:412–23.
5. Danik JS, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), measured
with an assay independent of apolipoprotein(a) isoform size, and risk
of future cardiovascular events among initially healthy women. JAMA
2006;296:1363–70.
6. Kamstrup PR, Benn M, Tybjærg-Hansen A, Nordestgaard BG.
Extreme lipoprotein(a) levels and risk of myocardial infarction in the
general population: the Copenhagen City Heart Study. Circulation
2008;117:176–84.
7. Rifai N, Ma J, Sacks FM, et al. Apolipoprotein(a) size and lipopro-
tein(a) concentration and future risk of angina pectoris with evidence
of severe coronary atherosclerosis in men: The Physicians’ Health
Study. Clin Chem 2004;50:1364–71.
8. Kamstrup PR, Tybjærg-Hansen A, Steffensen R, Nordestgaard BG.
Genetically elevated lipoprotein(a) and increased risk of myocardial
infarction. JAMA 2009;301:2331–9.
9. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated
with Lp(a) lipoprotein level and coronary disease. N Engl J Med
2009;361:2518–28.
10. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent
clinical trials for the National Cholesterol Education Program Adult
Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol
2004;24:e149–e161.
11. Reiner Z, Catapano AL, De BG, et al. ESC/EAS guidelines for the
management of dyslipidaemias: the Task Force for the management of
dyslipidaemias of the European Society of Cardiology (ESC) and the
European Atherosclerosis Society (EAS). Eur Heart J 2011;32:
1769 – 818.
12. Angelantonio E, Gao P, Pennells L, et al. Lipid-related markers and
cardiovascular disease prediction. JAMA 2012;307:2499–506.
13. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline
for assessment of cardiovascular risk in asymptomatic adults: a report
of the American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines. J Am Coll Cardiol
2010;56:e50–103.
14. Pencina MJ, D’Agostino RB Sr., D’Agostino RB Jr., Vasan RS.
Evaluating the added predictive ability of a new marker: from area
under the ROC curve to reclassification and beyond. Stat Med
2008;27:157–72.
15. Utermann G. Lipoprotein(a). In: Scriver CR, Sly WS, Childs B, et
al., editors. Metabolic and Molecular Bases of Inherited Disease.
11
1
1
2
2
2
2
2
2
2
2
1156 Kamstrup et al. JACC Vol. 61, No. 11, 2013
Lipoprotein(a) and Cardiovascular Risk Prediction March 19, 2013:1146–56New York, NY: McGraw-Hill, Medical Publishing Division, 2001:
2753– 87.
6. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Genetic evidence
that lipoprotein(a) associates with atherosclerotic stenosis rather than
venous thrombosis. Arterioscler Thromb Vasc Biol 2012;32:1732–41.
7. Kronenberg F, Kronenberg MF, Kiechl S, et al. Role of lipoprotein(a)
and apolipoprotein(a) phenotype in atherogenesis: prospective results
from the Bruneck study. Circulation 1999;100:1154–60.
8. Paultre F, Pearson TA, Weil HF, et al. High levels of Lp(a) with a
small apo(a) isoform are associated with coronary artery disease in
African American and white men. Arterioscler Thromb Vasc Biol
2000;20:2619–24.
9. Schnohr P, Jensen G, Lange P, Scharling H, Appleyard M. The
Copenhagen City Heart Study. Østerbroundersøgelsen. Tables with data
from the third examination, 1991-1994. Eur Heart J 2001;3:H1–83.
0. Clarke R, Shipley M, Lewington S, et al. Underestimation of risk
associations due to regression dilution in long-term follow-up of
prospective studies. Am J Epidemiol 1999;150:341–53.
1. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum2. Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex, and
menopausal status on plasma lipoprotein(a) levels. The Framingham
Offspring Study. Circulation 1993;87:1135–41.
3. Altman DG, Bland JM. Interaction revisited: the difference between
two estimates. BMJ 2003;326:219.
4. Phillips AN, Thompson SG, Pocock SJ. Prognostic scores for detect-
ing a high risk group: estimating the sensitivity when applied to new
data. Stat Med 1990;9:1189–98.
5. Harrell FE Jr., Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating
the yield of medical tests. JAMA 1982;247:2543–6.
6. Newson R. Efficient calculation of jackknife confidence intervals for
rank statistics. J Stat Soft 2006;15:1–10.
7. Newson R. Comparing the predictive powers of survival models using
Harrell’s C or Somers’ D. The Stata Journal 2010;10:339–58.
Key Words: coronary heart disease y lipoprotein(a) y risk prediction.
APPENDIX
For an expanded Methods section and supplemental tables and figures,levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with
nicotinic acid. J Intern Med 1989;226:271–6. please see the online version of this article.
Go to http://cme.jaccjournals.org
to take the CME quiz for this article.
